Angela MacFarlane

Ms. Macfarlane currently serves as CEO of Voyant Biotherapeutics, LLC, an early-stage biotech company dedicated to solving age-related macular degeneration. She founded and also serves as a Managing Partner of ForSight Labs, LLC an ophthalmic incubator formed in 2005 in partnership with Dr. Eugene de Juan, Jr. MD, and The Foundry. ForSight has started seven VISION companies in both therapeutics and medical devices — including Transcend Medical, Inc. (acquired by ALCON), ForSight Newco II, Inc. (acquired by QLT), NexisVision, Inc. (licensed), Forsight VISION4, Inc. (acquired by Roche), ForSight VISION5, Inc. (acquired by ALLERGAN), ForSight VISION6, Inc. (private/strategic partnership), and FSV7, LLC (private), focused on developing therapeutics for CNS disorders. Ms. Macfarlane served as the operating CEO of 3 ForSight companies, including as founding CEO through acquisition for ForSight VISION4, Inc. (Acquired by ROCHE), and ForSight VISION5, Inc., (Acquired by Allergan).

Previously, Ms. Macfarlane served as Chief Technology Counsel to The Foundry, a medical technology incubator, and Technology Counsel for Thomas J. Fogarty, M.D., a renowned physician/entrepreneur where she participated in the formation and/or development of 9 companies. She previously served on the senior management teams and counsel at TransVascular, Inc. (acquired by Medtronic), AneuRx, Inc. (acquired by Medtronic), and VidaMed Inc. (through IPO).

Ms. Macfarlane is an inventor on 25 U.S.-issued patents and received her BA in Business Administration from San Francisco State University, and her J.D. from Golden Gate University School of Law. She currently serves on the board of the Fogarty Institute for Innovation and is a mentor in the Ferolyn Powell Leadership Program.